SCHEMBL1604229

SCHEMBL1604229

CC(=O)OC(C)(C)CNC(=O)N[C@@H](C(=O)N1CC[C@](O)(c2ccc(Cl)cc2)C(C)(C)C1)C(C)C

nearest known ligand 0.82

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 20/20 0.82
NR1I2 O75469 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1604230 1.00 CCR1 (0.82) CCR1NR1I2
SCHEMBL12730338 1.00 CCR1 (0.82) CCR1NR1I2
SCHEMBL12797592 0.93 CCR1 (0.82) CCR1NR1I2
SCHEMBL12797593 0.93 CCR1 (0.82) CCR1NR1I2
SCHEMBL12730351 0.92 CCR1 (0.80) CCR1NR1I2
SCHEMBL12730334 0.92 CCR1 (0.80) CCR1NR1I2
SCHEMBL1604365 0.92 CCR1 (0.80) CCR1NR1I2
SCHEMBL12730790 0.92 CCR1 (0.80) CCR1NR1I2
SCHEMBL1604367 0.92 CCR1 (0.80) CCR1NR1I2
SCHEMBL12707938 0.92 CCR1 (0.80) CCR1NR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130178444-A1 PRODRUGS OF A PIPERIDINYL DERIVATIVE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL MYERS SQUIBB CO (US) 2013-07-11 US disclosed
US-20130178444-A1 PRODRUGS OF A PIPERIDINYL DERIVATIVE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL MYERS SQUIBB CO (US) 2013-07-11 US disclosed
US-20130178444-A1 PRODRUGS OF A PIPERIDINYL DERIVATIVE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL MYERS SQUIBB CO (US) 2013-07-11 US disclosed
US-8410139-B2 Prodrugs of a piperidinyl derivative as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2013-04-02 US disclosed
US-8410139-B2 Prodrugs of a piperidinyl derivative as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2013-04-02 US disclosed
US-8410139-B2 Prodrugs of a piperidinyl derivative as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2013-04-02 US disclosed
EP-2486013-A1 PRODRUGS OF A PIPERIDINYL DERIVATIVE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Bristol-Myers Squibb Company (US) 2012-08-15 EP disclosed
WO-2011044309-A1 PRODRUGS OF A PIPERIDINYL DERIVATIVE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY (US) 2011-04-14 WO disclosed
WO-2011044309-A1 PRODRUGS OF A PIPERIDINYL DERIVATIVE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY (US) 2011-04-14 WO disclosed
US-20110082113-A1 PRODRUGS OF A PIPERIDINYL DERIVATIVE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY 2011-04-07 US disclosed
US-20110082113-A1 PRODRUGS OF A PIPERIDINYL DERIVATIVE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY 2011-04-07 US disclosed
US-20110082113-A1 PRODRUGS OF A PIPERIDINYL DERIVATIVE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY 2011-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130178444-A1 PRODRUGS OF A PIPERIDINYL DERIVATIVE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY CCR7, CCR1, CCR2 CCR1 2/4885NR1I2 425/4885
US-20110082113-A1 PRODRUGS OF A PIPERIDINYL DERIVATIVE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY CCR7, CCR1, CCR2 CCR1 2/4885NR1I2 425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.